BRAF and melanoma: Among the metastatic patients, 17 of 40 (42.5%) resulted in melanomas harboring BRAF mutation, and 12 of them (70.6%), received BRAF +/- MEK inhibitors as first line of treatment; the treatment of the remaining patients is shown in Table 2.